Colorectal Cancer, Ovarian Metastasis
Conditions
Brief summary
This prospective, multi-center, real-world study is conducted to investigate the impact of different treatment strategies (systemic chemotherapy combined with oophorectomy or with other local treatment or chemotherapy alone) on the prognosis of ovarian metastatic colorectal cancer patients.
Detailed description
This study prospectively collects data of patients diagnosed with ovarian metastatic colorectal cancer, meeting inclusion criteria and signing the informed consent. Patients' treatment strategies and survival outcome in the real world will be faithfully recorded.
Interventions
None listed
Sponsors
Sun Yat-sen University
Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute
Changhai Hospital, Naval Medical University
West China Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed colorectal adenocarcinoma; 2. Histologically or radiologically diagnosed with ovarian metastasis, whether or not combined with metastases in other organs; 3. Women ≥18 years of age; 4. Eastern Cooperative Oncology Group performance status score ≤2; 5. Available imaging data if the disease is measurable according to RECIST criteria version 1.1; patients are eligible if there is no measurable lesion. 6. Complete medical records; 7. Informed consent form signed.
Exclusion criteria
1. Not ovarian metastatic colorectal cancer confirmed by radiology or histology; 2. Drug abuse or other medical, psychological and social disorders that would interfere with cooperation with the requirements of the study; 3. Other conditions that would influence patient compliance; 4. Pregnant or breastfeeding female; male and female unwilling to take any contraceptive measures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ovarian specific overall survival | up to 3 years | Calculated from the date of diagnosis with ovarian metastasis to death (caused by cancer) or last follow-up time. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ovarian specific objective response rate | 6 months | Response rate of ovarian metastases to systemic chemotherapy |
| Extra-ovarian specific objective response rate | 6 months | Response rate of extra-ovarian metastases to systemic chemotherapy |
| Progression free survival | 6 months | Survival time from treatment start to disease progression or death. |
| Quality of life questionnaire | 6 months | Quality of life during treatment |
Countries
China
Contacts
Primary ContactMeng Qiu, M.D.
Outcome results
None listed